Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections
[at noodls] – SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) — Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for life-threatening … more
View todays social media effects on TSRX
View the latest stocks trending across Twitter. Click to view dashboard